Participants

Executive Committee
Leigh Ann Arbuckle, USA, Treasurer’s Assistant
James Barrett, USA, Councilor
S. J. Enna, USA, President
Graeme Henderson, United Kingdom, First Vice President
Masamitsu Iino, Japan, Second Vice President
Lynn LeCount, USA, Administrative Officer
David LeCouteur, Australia, Secretary-General, Clinical Division
Francesca Levi-Schaffer, Israel, Councilor
Maria Isabel Lucena, Spain, Treasurer, Clinical Division
Eeva Moilanen, Finland, Councilor
Bhagirath Patel, India, Councilor
Michael Spedding, France, Secretary-General
Petra Thürmann, Germany, Treasurer
Yong-Xiang Zhang, PR China, Councilor

Unavailable
Darrell Abernethy, USA, Chair, Clinical Division
Patrick du Souich, Canada, Past President
David Webb, United Kingdom, Vice Chair, Clinical Division

Guest
Ying Zhao, PR China, Administrative Assistant

Discussion Topics

President’s welcome
President S. J. Enna thanked the Executive Committee members for their attendance. On behalf of the International Union of Basic and Clinical Pharmacology (IUPHAR) he acknowledged their past efforts and recognized the generosity of the Italian Society of Pharmacology for hosting the Executive Committee in conjunction with their 38th National Congress. He informed the group that Dr. Darrell Abernethy, Chair of the Clinical Pharmacology Division, had for health reasons recently resigned as Chair of the Division. The Executive Committee authorized an expenditure of up to US$200 to purchase a gift for Dr. Abernethy as an expression of gratitude for his service to IUPHAR.

Secretary-General’s comments
Secretary-General Michael Spedding described recent IUPHAR grant applications, giving particular credit to the Database Team at the University of Edinburgh for their work in preparing many of these. He reported that the Guide to Immunopharmacology database and its user interface are now in beta testing. Dr. Spedding believes that, in conjunction with ImmuPhar, the Immunopharmacology Section, IUPHAR can contribute significantly to the advancement of immunological therapeutics, one of the fastest growing areas in biomedical research. Although recent grant submissions to the Wellcome Trust and the International Council for Science (ICSU) were not approved, there are plans to submit in 2018 an Innovative Medicines Initiative grant requesting funds to expand further the Guide to Immunopharmacology.

Dr. Spedding is in the process of finalizing a contract to disseminate through the IUPHAR/British Pharmacological Society (BPS) Guide to Pharmacology the therapeutic targets being generated by the Medicines for Malaria Venture. The Medicines for Malaria Venture has successfully cloned the genome of the protozoan parasite, reproduced its proteins, and are now generating the phenotype profile to identify the most promising drug targets for designing novel therapeutics to prevent or treat this condition.
Dr. Spedding announced he had recently learned that the grant submitted by Dr. David Lewis, Chair of the IUPHAR Integrative and Organ Systems Pharmacology (IOSP) Initiative, and Dr. Bhagirath Patel, IUPHAR Councilor, was approved by the United Kingdom–India Education and Research Initiative. These funds will be used to underwrite two IOSP workshops in India and for transporting a group of Indian scientists to the United Kingdom for hands-on training. Dr. Enna paid tribute to Dr. Lewis’ enthusiasm and commitment to foster training in pharmacology.

Currently under review is a joint United Kingdom-Thailand grant application that, if funded, would make it possible to add natural product therapeutic targets to the Guide to Pharmacology. Also in progress is a European Cooperation in Science and Technology grant application being prepared by Profs. Francesca Levi-Schaffer and Katherine Tiligada, the ImmuPhar Chair and Treasurer, respectively. If awarded, these funds would be used to identify and categorize “druggable” antibody targets. Dr. Spedding will continue his collaborations with the Brazilian Society of Pharmacology and Experimental Therapeutics, the Indian Pharmacological Society, and the Pharmacology for Africa (PharFA) initiative to identify pharmacology-related grant opportunities for developing countries. In particular, support is being sought for funding pharmacology education, development of clinical pharmacology, and efforts to reconcile the results of natural product empirical studies with those obtained using traditional biomedical research techniques.

Recently, the IUPHAR Clinical Pharmacology Division approved the Karolinska Institutet in Stockholm, Sweden as the sixth Clinical Pharmacology Mentoring Center. This was accomplished with the support of Dr. Lars Gustafsson, the IUPHAR Chair of the Clinical Pharmacology in Developing Countries. In addition, Dr. Spedding is communicating with Dr. Magnus Ingelman-Sundberg about IUPHAR joining together with the Karolinska Institutet to cross-match 20 drug targets from the Guide to Pharmacology with HIV metabolites. The goal is to perform a pilot study, the results of which would be used to attract funding for a pharmacogenetics research project in Africa.

Dr. Spedding encouraged the Executive Committee members to seek out opportunities to organize IUPHAR-related meetings in conjunction with larger conferences. He cautioned them, however, about being assigned the last slot on the meeting agenda because audience attendance is typically low for final meeting presentations, and he noted that stand-alone meetings are more financially risky. Dr. Spedding believes a good way to increase the impact and visibility of IUPHAR is to require organizers of meetings supported with IUPHAR funding to publish a special issue in an IUPHAR-selected journal that contains articles written by the speakers and other prominent participants.

Dr. Enna thanked Dr. Spedding for his immense efforts in organizing grant applications for funds to support IUPHAR activities. He noted that in addition to the time required to prepare these applications, there are additional demands on Michael’s time once a project is funded as he must oversee the execution of the work. Dr. Enna stressed the need to continue seeking ways to increase the pool of unrestricted IUPHAR funds to help ensure the survival of the Union and to provide seed money for new initiatives.

Treasurer’s report

Treasurer Petra Thürmann summarized the handouts providing specifics about IUPHAR finances. She advised that the limited 2016 financial audit, performed by Dufour Treuhand of Switzerland, is satisfactory. She reminded the Executive Committee that in 2016 Dufour Treuhand recommended that a Swiss notary public be retained to revise the IUPHAR Statutes to comply with the Canton of Basel regulations governing external auditing of not-for-profit organizations such as IUPHAR. The reports on the 2016 financials received from the IUPHAR internal auditors, Profs. Kathy Knights and Johannes Knollmeyer, were positive.

The 2017 Actual vs. Projected Income and Expenses as of September 30th of this year were presented by Dr. Thürmann. She noted the efforts of Ms. Leigh Ann Arbuckle, the IUPHAR Treasurer’s Assistant, which have resulted in the collection of ~US$105k thus far of the budgeted US$111k in membership dues for 2017. It was noted that Ms. Arbuckle has found contact information for the current Treasurers of two European member societies that are arrears in dues payments. Ms. Arbuckle is optimistic that overall IUPHAR will achieve the
projected 2017 income of US$163.5k. As of September 30th, IUPHAR has accumulated ~US$120k for the year. Dr. Ying Zhao reported that Yantai University has initiated payment of their second installment in support of the IUPHAR Pharmacology Education Project (PEP). It is anticipated this will be received during the current calendar year.

The expenditures as of September 30, 2017 were reported as ~US$87k. This includes six months of administrative staff salaries, the annual stipend to the Clinical Pharmacology Division, support of Section activities, preliminary expenses associated with the planned clinical pharmacology workshops in China, the annual membership dues paid to the International Council of Science and the International Council for Laboratory Animal Sciences (ICLAS), and two-thirds of the annual costs associated with the IUPHAR.org website. Dr. Thürmann anticipates that after receiving the remaining pledged donations, paying for the Executive Committee and Paris Nomenclature Committee (NC-IUPHAR) meetings and the remaining salaries of the administrative staff, that IUPHAR expenses for 2017 will exceed income by approximately US$5k. She expressed gratitude to the Italian Society of Pharmacology for generously covering the costs of the Executive Committee local expenses in Rimini. Dr. Thürmann reminded the group that these estimates do not take into account the year-end gain or loss in the value of the IUPHAR investments.

Dr. Thürmann prefaced the 2018 budget projection by explaining it contained only those items that could be quantified as of September 30, 2017. She noted the Executive Committee will be making decisions soon on naming a new Executive Officer and Administrative Office. These will have a significant impact of the 2018 budget projections. Ms. Arbuckle estimates for 2018 operational income of US$126.5k, of which US$120k is from dues, with ~US$107.5k in projected operational expenses. She noted that the 2018 projected expense figure reflects the salaries for the current administrative staff and website expenses through July 31, 2018. The 2018 budget will be revised to reflect the Executive Committee decisions concerning the appointment of a new Executive Officer and the relocation of the Administrative Office. The 2018 projections include estimated Executive Committee travel expenses associated with the Kyoto World Congress, the IUPHAR booth and the staff travel to Kyoto in early July.

Overview of activity reports

Dr. Spedding noted that the activity reports for the IUPHAR Committees, Clinical Pharmacology Division, Sections and Subcommittees are all included with the materials sent earlier in conjunction with this meeting. He asked if there were any questions concerning these reports. As there were none, he invited the Division and Section officers present to update the Executive Committee on any activities since the reports were submitted.

Clinical Pharmacology Division

The Clinical Pharmacology Division Secretary, Dr. David LeCouteur, commented that the Clinical Pharmacology Division Mentoring Centers are gathering momentum. He reported that a Thai pharmacist, under the supervision of Dr. Sarah Hilmer, the Chair of the Geriatric Clinical Pharmacology Subcommittee, has surveyed the IUPHAR member societies as she prepares a composite curriculum for geriatric pharmacology training. A manuscript is in preparation to report on this effort. Although the clinical pharmacology training workshops scheduled in China had to be canceled at the last minute, Dr. LeCouteur noted the Clinical Pharmacology Division officers hope to identify faculty to reschedule the training during 2018.

The Clinical Pharmacology Division Treasurer, Dr. María Isabel Lucena, summarized its finances. Although funds are very limited, during 2017 the Division supported symposia and workshops in Mumbai, India, and San Francisco, USA. The Division also covered the annual membership fees of the Council for International Organizations of Medical Sciences (CIOMS). The attendance of Dr. Lucena to the CIOMS Executive meeting and General Assembly was free of charge as the expenses were covered by CIOMS.

World Health Organization (WHO)

2018-2022 Liaison Committee

Dr. Spedding announced that because Dr. Kalle Hoppu, Chair of the 2014-2018 Liaison Committee to WHO, has retired he will not continue on the Liaison
Committee after July, 2018. Dr. Thürmann commented on the need to identify a clinical pharmacologist living in or near Geneva who could represent IUPHAR during the periodic WHO meetings. She pointed out the value of appointing an individual to evaluate the WHO communications to determine which WHO projects or initiatives coincide with IUPHAR objectives so that efforts can be made to coordinate activities. Dr. Enna asked the members of the Clinical Pharmacology Division to recommend to the IUPHAR officers some possible candidates who would be willing to serve as our 2018-2022 representative to WHO.*

Dr. Thürmann informed the Executive Committee that the WHO NGO status of IUPHAR must be renewed next year. Dr. Hoppu and the IUPHAR Administrative Officer, Ms. Lynn LeCount, have completed the majority of the online WHO Non-State Actor application. The completed NGO renewal application is due in June, 2018. A critical portion of this document is the WHO/IUPHAR collaborative plan. Dr. Spedding asked the Clinical Pharmacology Division to identify one or two individuals who might be willing to help finalize this document.*

Pharmacology of Natural Products
Councilor Yongxiang Zhang reported the Pharmacology of Natural Productions Section organized with Dr. Cherry Wainwright of Robert Gordon University, under the auspices of the International Conference on the Mechanism of Action of Nutraceuticals, a conference held in Aberdeen, Scotland this past September. The next Pharmacology of Natural Products Section conference is scheduled for 2019. IUPHAR Councilor Bhagirath Patel offered to consult his fellow officers of the Indian Pharmacological Society about possibly hosting the 2019 natural product conference in conjunction with the annual meeting of the Indian Society scheduled for Hyderabad in late 2019*. It was also announced that next week the Chinese Pharmacological Society is hosting in Beijing a joint meeting with the American Society for Pharmacology and Experimental Therapeutics. The theme of this joint meeting is the use of natural products in clinical pharmacology. Dr. Zhang reported the Chinese Pharmacological Society is requesting Chinese government funding to underwrite the creation of a natural product target database.

ImmuPhar
Councilor Francesca Levi-Schaffer summarized the recent activities of ImmuPhar, the IUPHAR Immunopharmacology Section. The section will be sponsoring a symposium and hold a meeting during the 2017 British Pharmacological Society annual meeting to be held in London in December. She noted the speakers are traveling mainly at their own expense. Plans are underway to present a symposium and conduct a Section business meeting during WCP2018 in Kyoto. Prof. Levi-Schaffer reported that the Immunopharmacology Section is collaborating with the International Union of Immunological Sciences President, Dr. Alberto Mantovani, in preparing a grant application seeking funds to support the preparation of the Guide to Immunopharmacology. Dr. Spedding noted that while in Brazil recently he learned that Dr. Mauro Teixeira, the Immunopharmacology Section Vice Chair, is preparing a list of potential experts who will be invited to serve on a joint committee of IUPHAR and the International Union of Immunological Sciences.

Membership Committee
Dr. Enna reported that during 2017 the Malaysian Society of Pharmacology and Physiology, and the Irish Association of Pharmacologists were granted full membership in IUPHAR. The Pharmacology Society of the Myanmar Medical Association was invited to join as an IUPHAR Benefactor.

Tasks from the last Executive Committee meetings
Dr. Enna summarized the status of the tasks assigned during the Executive Meetings last year in Melbourne. Councilor James Barrett has received a proposal from a major publisher offering an annual cash payment to IUPHAR in exchange for publication of IUPHAR-sanctioned reports and editorial board participation. The group discussed the advantages and disadvantages of
the offer as it relates to current publishing agreements with member societies. While the
group felt the proposal was good, some felt the amount of compensation offered was
somewhat low. Dr. Barrett will communicate further with the publisher about the terms of
the agreement.*

Dr. Barrett reported on discussions he has had with colleagues involved in academic drug
discovery. While his contacts agreed in principal that there could be merit in forming an
IUPHAR Section in this area, questions remained about how the role IUPHAR would
play in advancing the goal of the existing centers and programs involved in academic
drug discovery. Dr. Barrett will draft a proposal to help clarify this issue and to more
precisely define the mission of an IUPHAR Section on Academic Drug Discovery. He will
use this document to solicit opinions from participants at a drug discovery conference in
December.* After receiving this feedback he will decide whether there is sufficient
interest among these members of the scientific community to seek Executive Committee
approval for the establishment of an IUPHAR Section on Academic Drug Discovery.

Dr. Spedding has spoken with Dr. Lars Gustafsson, the chair of the Clinical Pharmacology in
Developing Countries Subcommittee of the IUPHAR Clinical Division, and Dr. Kalle
Hopppu, chair of the IUPHAR Liaison Committee to the WHO, to determine how IUPHAR
could further support the attainment of WHO objectives.

Proposals to host the new IUPHAR Executive Officer position were solicited from IUPHAR
member societies. Dr. Thürmann believes that, in addition to providing funds to support a
central administrative office, the Secretary-General and Treasurer should receive a small
annual budget to defray the cost of local secretarial support. Proposals to host the
IUPHAR Administrative Office was received from the Parthenon Management Group, a
wholly owned subsidiary of the American College of Neuropsychopharmacology, and
from the Chinese Pharmacological Society.

Dr. Zhang clarified that the Chinese Pharmacological Society is more interested in hosting
an IUPHAR branch or satellite facility than the IUPHAR Administrative Office. He feels a
satellite office in China could assist IUPHAR in coordinating sponsored scientific
meetings, workshops and events in Asia. He indicated that the Chinese Pharmacological
Society could seek support from the Chinese Association of Science and Technology for
such an office, which would help further the overall goals of IUPHAR. An ad hoc
committee was formed, composed of First Vice President Graeme Henderson, Second
Vice President Masamitsu Iino, Dr. LeCouteur, and Dr. Zhang, to explore potential roles
and tasks that might be assigned to a Beijing branch office of IUPHAR.* Dr. Spedding
will chair the ad hoc committee.

Dr. Enna summarized the components of the proposal received from the Parthenon
Management Group to operate the IUPHAR Administrative Office, including the
appointment of a part-time Executive Officer. He noted that this group is already serving
under contract as the administrative office for more than a dozen scientific societies. The
Executive Committee discussed various ways to configure the administrative tasks with
the goal of keeping the IUPHAR Administrative Office within the domain of the
pharmacology societies while retaining the institutional memory that in the past was lost
with the election of a new Secretary-General. However, none of the proposed plans was
felt to be superior to that proposed by the Parthenon Management Group. Dr. Spedding
summarized financial projections for 2018 and 2019 to illustrate how transitioning the
IUPHAR administrative office to the Parthenon Management Group will affect the
IUPHAR budget in the near-term. Following further discussion, Dr. Spedding moved that
IUPHAR sign a contract with Parthenon Management Group to oversee the
establishment and operation of the IUPHAR Administrative Office based on the terms
specified in their proposal. Dr. Barrett seconded the motion. The motion was
unanimously approved by the Executive Committee. The IUPHAR officers will inform
Parthenon Management Group of this decision.*

As directed by the Executive Committee, Drs. Enna and Spedding obtained from Drs. David
Lewis and J.R. Haywood their opinions regarding the value to IUPHAR maintaining its
membership in ICLAS. Dr. Enna reminded the group that this question had been raised
because there has been no communication, aside from membership dues invoices, from
ICLAS in several years. A motion was made to terminate IUPHAR membership in ICLAS in 2018. Dr. Thürmann seconded the motion, which was approved unanimously by the Executive Committee.

Ms. LeCount included on the 2018 General Assembly draft agenda the appointment of Dufour Treuhand as the IUPHAR external auditor. Dr. Thürmann reported that, as recommended by Dufour Treuhand, she is investigating the cost of hiring a Swiss notary public to revise the IUPHAR Statutes to more fully align with the laws of Basel Canton. Dr. Enna added that another Statute change being considered is authorization to give the Executive Committee the ability to designate individuals who are not currently serving on the Executive Committee to be the IUPHAR representatives to WHO and ICSU. The IUPHAR officers believe Dr. Urs Ruegg has been an exceptional IUPHAR representative to ICSU and wish to invite him to continue in that role until 2022. The Executive Committee members approved the proposal for the Statutes to be revised for consideration by the voting delegates during WCP2018 in Kyoto.

Dr. Spedding explained that the NC-IUPHAR has benefited greatly by the appointment of corresponding members as it allows the Committee to expand its intellectual capital at very little expense. He suggests that the IUPHAR Executive Committee consider the appointment of corresponding members as well to expand its reach and influence. Dr. Henderson recommended that the terms for Executive Committee corresponding members be the four years between the World Congresses or the conclusion of the corresponding member’s project, whichever occurred first. While the Executive Committee approved of the idea of adding corresponding members to the 2018-2022 Executive Committee, they felt it was more appropriate for the 2018-2022 Executive Committee to make the final decision on this matter as it will be most affected by this change. Dr. Spedding will update his position description for corresponding members and the list of potential individuals that could be considered for such appointments by the 2018-2022 Executive Committee. He will circulate the final version of the position description and candidate list by email to ensure the current Executive Committee is comfortable making these recommendations to the 2018-2022 Executive Committee.*

The Executive Committee members discussed the role a young investigator and the process for selecting such an individual to serve as an ad hoc member of the group. Dr. Spedding emphasized the importance of having a member of the Executive Committee serve as a mentor for the young investigator and to monitoring the social media postings that would be overseen by the young investigator. The group felt that appointing young investigator(s) as corresponding members would be most appropriate and not require any change in Statutes. Dr. Levi-Schaffer proposed, and the group agreed, that all IUPHAR member societies be asked to nominate young investigators from their organizations for these posts. It was decided to limit the nominations to one young investigator per IUPHAR member society and that the nominees must be within five years of receiving their terminal degree. Dr. Spedding and Ms. LeCount will coordinate the call for nominations. The finalists will be selected by the 2018-2022 Executive Committee.

The 2014-2018 Executive Committee members reviewed the slate of candidates proposed by the Nominating Committee of those volunteers to serve on the 2018-2022 Executive Committee if they are approved by the voting delegates during the WCP2018 General Assembly. Some issues were raised about the nominees that the IUPHAR officers will discuss with the Nominating Committee. Ms. LeCount will arrange a teleconference for the IUPHAR officers to communicate with Dr. Kim Brøsen, the Nominating Committee Chair. Once the list of nominees is finalized, Ms. LeCount will forward it to the 2014-2018 Executive Committee members for informational purposes. Dr. Enna acknowledged the efforts and time expended by Dr. Brøsen and his committee in preparing this slate of candidates.

Dr. Thürmann expressed concern about not receiving Pharmacology International, the IUPHAR newsletter, through the German Society for Experimental and Clinical Pharmacology and Toxicology, of which she is a member. As the IUPHAR newsletter appears only twice a year, she feels member societies should distribute these to their
ms. LeCount indicated that when the newsletter is sent to IUPHAR member society officers the cover letter includes a request that they post it on their society websites or forward it directly to their members. She indicated that she knows a few societies abide by this request. Dr. Enna volunteered to draft a correspondence to be emailed individually to IUPHAR member society officers stressing the importance of their sharing Pharmacology International with their membership.* Dr. Thürmann asked the Executive Committee members to encourage their own societies to forward Pharmacology International to their members and/or to post it on their websites.

2018-2022 Appointments and Volunteers
Ms. LeCount led the discussion to identify potential volunteers to serve as the 2018-2022 Internal Auditors and Membership Committee members. In the coming months Dr. Thürmann and Ms. Arbuckle will consider the suggested names for Internal Auditors so that the final candidate selections will be known to the IUPHAR Executive Committee by April 2018 in anticipation of the General Assembly vote in July. The IUPHAR officers will recommend names for appointment to the Membership Committee after receiving recommendations from the Executive Committee. Dr. Spedding hopes that the members of the 2018-2022 Membership Committee will become actively engaged in recruiting new organizations for membership in IUPHAR. He would also like to identify how to expand clinical pharmacology in South America. During a trip to Brazil he learned that clinical trials there and in other South American countries are generally designed and overseen by pharmaceutical firms rather than clinical pharmacologists. Dr. Thürmann noted, however, that the number of clinical pharmacologists and the extent to which they participate in research is usually determined by local regulations rather than pharmacology societies. For this reason she believes it would be difficult to translate the European model of clinical pharmacology to other areas of the world. Dr. Spedding suggested the pharmacological societies could develop a role as being a hub or even a ‘club’ for the different clinical scientists involved in clinical trials, otherwise controlled by pharmaceutical societies. Dr. Spedding will monitor, and give advice, on the situation in Brazil.

Dr. Enna informed the Executive Committee that Dr. Henderson has agreed to serve as the Chair and Dr. Thürmann as Vice-Chair of the 2022-2026 Nominating Committee. Working together Drs. Henderson and Thürmann will identify three other individuals to serve as members on this committee. Dr. Henderson will communicate the names of all of the committee member candidates to Ms. LeCount by the end of April so they can be forwarded to the voting delegates for election during the General Assembly in Kyoto. *

Dr. Spedding agreed to contact Dr. Steve Alexander to confirm his willingness to continue as the Chair of the Nomenclature Committee (NC-IUPHAR) for 2018-2022. Dr. Spedding believes that carefully curated databases will have a central role in the future activities of IUPHAR.

World Congresses of Basic and Clinical Pharmacology (WCP)
WCP2026 proposals
Dr. Enna noted the high level of interest in hosting IUPHAR World Congresses as evidenced by the receipt of nine proposals to sponsor the meeting in 2026:
Bangkok, from the Pharmacological and Therapeutic Society of Thailand
Budapest, from the Hungarian Society for Experimental and Clinical Pharmacology
Daegu, from the Korean Society of Pharmacology
Florence, from the Italian Pharmacological Society
Havana, from the Cuban Society for Pharmacology
Kuala Lumpur, from the Malaysian Society of Pharmacology and Physiology
Melbourne, from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists
Montreal, from the Canadian Society of Pharmacology and Therapeutics
Prague, from the Czech Society for Experimental and Clinical Pharmacology and Toxicology

The Executive Committee agreed that nine presentations would exceed the time available for consideration of this matter during the General Assembly scheduled for July 4th, 2018.
Dr. Enna proposed, and the Executive Committee members endorsed, that the WCP2014 voting delegates be asked to participate in an electronic vote to select the top four WCP2026 bids for consideration by the WCP2018 voting delegates next year. Dr. Enna and Ms. LeCount will inform the WCP2026 bidders about the triage process as well as organize the WCP2014 delegate vote.*

WCP2022 Activity Update
Dr. Henderson announced that the BPS, the WCP2022 organizers, will be advertising the Congress during WCP2018. The BPS has purchased appropriate domain names and anticipate that the congress website will be launched in March or April, 2018. He mentioned that BPS has encumbered £5M to ensure WCP2022 results yields a profit for IUPHAR.

WCP2018 Activity update
Dr. Iino summarized the activity of the WCP2018 organizers since his report to the Executive Committee was sent a few months ago. Abstracts may be submitted through WCP2018.org from August 1st through December 14th. Among those oral or poster abstracts, the WCP2018 Program Committee will choose speakers to present during the Oral Sessions, which are scheduled separately from the Symposia. The registration fee for students has been maintained at ¥10,000 (<US$100) to encourage their participation. The WCP2018 organizers have appointed a Young Investigator Committee to ensure there are events during the Congress to engage young scientists from all cultures. Due to cost constraints, the WCP2018 organizers have decided not to ask a member of the Japanese Royal Family to be present during the Opening Ceremony. Dr. Iino noted that the traditional Japanese venue being considered for the WCP2018 Presidential Dinner is limited to 50 participants. Given this constraint, the WCP2018 organizers must know soon the number of IUPHAR Executive Committee members who will be attending this event so that they can determine how many other dignitaries may be invited.

After learning that the Executive Committee members need assistance to finalize their Kyoto hotel reservations, Dr. Iino and the Administrative Officer, Ms. Lynn LeCount, will put them in touch with the WCP2018 travel agent to accomplish this task.*

Young Investigator Competition
The Executive Committee members agreed to evaluate the Young Investigator abstract submissions in early January, sending Ms. LeCount the names of their top candidates. From among this pool of recommended abstracts, the IUPHAR officers will choose the finalists who will make an oral presentation describing their research during the Young Investigators Competition. All Executive Committee members who are not otherwise engaged as a speaker at the time of the Young Investigator Competition will serve as judges during the oral presentations in Kyoto.

Establish voting procedures/delegate registration
Dr. Enna briefly described the plan for registering the voting delegates at the IUPHAR booth in advance of the General Assembly. An envelope containing the voting ballots will then be handed to each registered delegate once everyone is seated for the General Assembly.

General Assembly draft agenda
Following a few minor changes, the Executive Committee approved the current draft of the agenda for the WCP2028 General Assembly.

Next Executive Committee meetings
Dr. Enna reminded everyone that the next Executive Committee meetings will be held in Kyoto, Japan in conjunction with WCP2018 during the first week of July, 2018. Dr. Thürmann announced the amounts of the travel stipends to be paid to the 2014-2018 Executive Committee members to help defray their cost to participate in the Kyoto IUPHAR 2014-2018/2018-2022 joint Executive Committee meetings. She explained the travel stipends were calculated by region to cover the cost of an economy flight Kyoto, two hotel nights, and public transportation to/from the airport.
Dr. Enna asked Councilor Patel whether he believed the Indian Pharmacological Society would have an interest in hosting the IUPHAR 2019 Executive Committee meeting during the possible conference with the Pharmacology of Natural Products Section. Councilor Patel will bring the topic before the officers of the Indian Pharmacological Society in February 2018. He will report on the outcome of his February discussion during the IUPHAR Executive Committee meeting in Kyoto.

Dr. Spedding and Ms. LeCount reminded everyone of the tasks resulting from the Executive Committee discussions.

Dr. Spedding concluded the meeting at 1:55 p.m. CEST.

Lynn LeCount, CMA
Administrative Officer

* Action Items

The Clinical Pharmacology Division will consider potential volunteers to serve on the 2018-2022 WHO Liaison Committee.

The Clinical Pharmacology Division will consider potential volunteers to draft an IUPHAR-WHO Collaborative Action Plan for submission by June 2018 along with the WHO NGO renewal application.

Dr. Patel will contact the officers of the Indian Pharmacological Society to explore the possibility of hosting in 2019 an IUPHAR Executive Committee meeting and/or the Conference on the Pharmacology of Natural Products. The conference would be organized in collaboration with the IUPHAR Pharmacology of Natural Products Section and the Chinese Pharmacological Society.

Dr. Barrett communicate to the publisher proposing an affiliation with IUPHAR the issues raised during the Executive Committee meeting concerning the terms of any agreement.

Dr. Barrett will draft a proposal to clarify the mission and goals of an IUPHAR Section on Academic Drug Discovery that will be used to obtain comments and suggestions, and to gauge the level of enthusiasm, of those working in this field.

The IUPHAR officers will inform the Parthenon Management Group that their contract proposal to establish and manage the IUPHAR Administrative Office was accepted by the Executive Committee.

Drs. Henderson, Iino, LeCouteur, Spedding and Zhang will explore potential roles and tasks that could be assigned to a Beijing branch office of IUPHAR.

Dr. Spedding will circulate to the 2014-2018 Executive Committee members a revised position description of corresponding members so a recommendation may be made to the 2018-2022 Executive Committee members in Kyoto.

Dr. Spedding and Ms. LeCount will solicit from the IUPHAR member societies one Young Investigator nominee to serve on the 2018-2022 Executive Committee. The finalist will be chosen by the members of the 2018-2022 Executive Committee.

Dr. Enna volunteered to draft an email to be sent individually to the officers of the IUPHAR member societies stressing the importance of sharing Pharmacology International with their membership.
Dr. Henderson will communicate the names of all of the committee member candidates to Ms. LeCount by the end of April so they can be forwarded to the voting delegates for election during the General Assembly in Kyoto.

Dr. Enna and Ms. LeCount will inform the WCP2026 bidders about the need for a preliminary vote to reduce the list to four oral presentations and will organize the 2014 WCP delegate voting process concerning this matter.

Dr. Iino and Ms. LeCount will send the Executive Committee members the contact information necessary for reserving a hotel room for the Kyoto meeting.